Candel Therapeutics not addressing metastatic PDACApril 04, 2024 - Candel Therapeutics oncolytic virus (herpes virus) addresses borderline resectable pancreatic ductal adenocarcinoma (PDAC) and not metastatic PDAC, in which ONCY's pelareorep + immune checkpoint inhibitors has demonstrated related postive results.
https://www.onclive.com/view/can-2409-plus-valacyclovir-generates-positive-phase-2-survival-results-in-pdac
A borderline resectable pancreatic ductal adenocarcinoma (BR-PDAC) is a tumor with limited vascular involvement that is technically resectable but with a high risk of positive margins (R1 resection).
https://www.dovepress.com/borderline-resectable-pancreatic-cancer-challenges-for-clinical-manage-peer-reviewed-fulltext-article-CMAR